Sugi Predict

Sugi Predict / Compounds / SCHEMBL992446

SCHEMBL992446

SCHEMBL992446

O=C(O)c1ccc(NCc2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.76

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HCAR3 P49019 12/20 0.68
▸ L3MBTL1 Q9Y468 1/20 0.66
▸ KMT2A Q03164 4/20 0.62
▸ PKM P14618 1/20 0.62
▸ MAPT P10636 4/20 0.60
▸ MEN1 O00255 3/20 0.60
▸ GAA P10253 1/20 0.60
▸ LMNA P02545 1/20 0.58
▸ NPC1 O15118 1/20 0.58
▸ RECQL P46063 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9822953 0.89 KMT2A (0.59) HCAR3L3MBTL1KMT2APKMMAPT
SCHEMBL29117538 0.89 KMT2A (0.59) HCAR3L3MBTL1KMT2APKMMAPT
SCHEMBL30590597 0.89 KMT2A (0.59) HCAR3L3MBTL1KMT2APKMMAPT
SCHEMBL28550092 0.87 CDC25B (0.72) HCAR3L3MBTL1KMT2APKMMAPT
SCHEMBL15687598 0.87 POLB (0.61) HCAR3L3MBTL1KMT2APKMMAPT
SCHEMBL6044345 0.85 HCAR3 (0.64) HCAR3KMT2AMAPTRECQL
SCHEMBL6044296 0.85 MAPT (0.69) HCAR3KMT2AMAPTMEN1GAA
SCHEMBL1843232 0.84 MAPT (0.68) HCAR3L3MBTL1KMT2AMAPTMEN1
SCHEMBL6044783 0.84 MAPT (0.67) HCAR3KMT2AMAPTMEN1GAA
SCHEMBL1841502 0.84 MAPT (0.56) HCAR3L3MBTL1KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100196-A1 Substituted amines for the treatment of alzheimer's disease ELAN PHARMACEUTICALS, INC. 2006-05-11 — — US claimed
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-05-08 — — US disclosed
CN-119923385-A Inhibitors of RNA helicase DHX9 and uses thereof 埃克森特治疗公司 2025-05-02 — — CN disclosed
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof ACCENT THERAPEUTICS, INC. (US) 2025-02-25 — — US disclosed
EP-4479138-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 — — EP disclosed
US-12162867-B2 Inhibitors of RNA helicase DHX9 and uses thereof ACCENT THERAPEUTICS, INC. (US) 2024-12-10 — — US disclosed
US-20240316047-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2024-09-26 — — US disclosed
US-20240279210-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2024-08-22 — — US disclosed
WO-2023154519-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-17 — — WO disclosed
EP-2454253-B1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES MERCK PATENT GMBH (DE) 2015-01-21 — — EP disclosed
CN-102471317-B Aminopyridine derivatives for treating tumors and inflammatory diseases MERCK PATENT GMBH 2014-02-26 — — CN disclosed
US-8648201-B2 Aminopyridine derivatives for treating tumors and inflammatory diseases MERCK PATENT GMBH (DE) 2014-02-11 — — US disclosed
EP-2454253-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES Merck Patent GmbH (DE) 2012-05-23 — — EP disclosed
CN-102471317-A Aminopyridine derivatives for treating tumors and inflammatory diseases MERCK PATENT GMBH 2012-05-23 — — CN disclosed
US-20120115861-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-05-10 — — US disclosed
WO-2011006567-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES MERCK PATENT GMBH (DE) 2011-01-20 — — WO disclosed
US-20060122240-A1 Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof ARENA PHARMACEUTICALS, INC. (US) 2006-06-08 — — US disclosed
WO-2004041274-A1 BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2004-05-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316047-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX29, DHX9, DDX39B HCAR3 3678/4885L3MBTL1 543/4885KMT2A 2263/4885
US-20060100196-A1 Substituted amines for the treatment of alzheimer's disease BACE1, APP, BACE2 HCAR3 2295/4885L3MBTL1 3425/4885KMT2A 1649/4885
US-20240279210-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX29, DHX9, DDX39B HCAR3 3693/4885L3MBTL1 772/4885KMT2A 2203/4885
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof DHX29, DHX9, DDX39B HCAR3 3678/4885L3MBTL1 543/4885KMT2A 2263/4885
US-12162867-B2 Inhibitors of RNA helicase DHX9 and uses thereof DHX29, DHX9, DDX39B HCAR3 3693/4885L3MBTL1 772/4885KMT2A 2203/4885
US-20120115861-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES PDK1, PDK2, PDK4 HCAR3 1236/4885L3MBTL1 1906/4885KMT2A 1075/4885
US-20060122240-A1 Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof GCGR, GPR119, HMGCR HCAR3 85/4885L3MBTL1 4100/4885KMT2A 2238/4885
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B HCAR3 3674/4885L3MBTL1 564/4885KMT2A 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.